Why Is Intel Struggling Against AMD?
Due to its disappointing reports, so-so management, and lack of…
Sell
50
BDULF Quote, Financials, Valuation and Earnings
Last price:
$0.70
Seasonality move
:
2.38%
Day range:
$0.70 - $0.70
52-week range:
$0.65 - $0.85
Dividend yield:
3.17%
P/E ratio:
24.31x
P/S ratio:
3.63x
P/B ratio:
3.80x
Volume:
--
Avg. volume:
133
1-year change:
-14.03%
Market cap:
$11.1B
Revenue:
$3.1B
EPS (TTM):
$0.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDULF
Bangkok Dusit Medical Services PCL
|
-- | -- | -- | -- | -- |
|
BUGDF
Bumrungrad Hospital PCL
|
-- | -- | -- | -- | -- |
|
CVM
CEL-SCI
|
-- | -- | -- | -- | $8.00 |
|
IGC
IGC Pharma
|
$305K | -$0.02 | 3.39% | -50% | $3.88 |
|
NIVF
NewGenIvf Group
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDULF
Bangkok Dusit Medical Services PCL
|
$0.70 | -- | $11.1B | 24.31x | $0.01 | 3.17% | 3.63x |
|
BUGDF
Bumrungrad Hospital PCL
|
$7.91 | -- | $6.3B | 31.15x | $0.09 | 1.86% | 9.41x |
|
CVM
CEL-SCI
|
$0.27 | $8.00 | $21.1M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma
|
$0.29 | $3.88 | $22.8M | -- | $0.00 | 0% | 16.82x |
|
NIVF
NewGenIvf Group
|
$0.31 | -- | $527.4K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDULF
Bangkok Dusit Medical Services PCL
|
9.5% | -0.568 | 2.25% | 0.94x |
|
BUGDF
Bumrungrad Hospital PCL
|
0.09% | -0.086 | 0.01% | 4.21x |
|
CVM
CEL-SCI
|
-- | 1.752 | -- | -- |
|
IGC
IGC Pharma
|
2.1% | -1.475 | 0.51% | 0.21x |
|
NIVF
NewGenIvf Group
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDULF
Bangkok Dusit Medical Services PCL
|
$304.7M | $156.2M | 14.33% | 15.75% | 19.66% | $11.1M |
|
BUGDF
Bumrungrad Hospital PCL
|
$94.5M | $62.3M | 29.88% | 29.91% | 33.84% | $59.5M |
|
CVM
CEL-SCI
|
-- | -$6.9M | -- | -- | -- | -$4.2M |
|
IGC
IGC Pharma
|
$104K | -$1.9M | -114.2% | -116.24% | -730.74% | -$1.4M |
|
NIVF
NewGenIvf Group
|
-- | -- | -- | -- | -- | -- |
Bangkok Dusit Medical Services PCL vs. Competitors
-
Which has Higher Returns BDULF or BUGDF?
Bumrungrad Hospital PCL has a net margin of 15.81% compared to Bangkok Dusit Medical Services PCL's net margin of 29.4%. Bangkok Dusit Medical Services PCL's return on equity of 15.75% beat Bumrungrad Hospital PCL's return on equity of 29.91%.
Company Gross Margin Earnings Per Share Invested Capital BDULFBangkok Dusit Medical Services PCL37.83% $0.01 $3.3B BUGDFBumrungrad Hospital PCL49.65% $0.06 $814M -
What do Analysts Say About BDULF or BUGDF?
Bangkok Dusit Medical Services PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand Bumrungrad Hospital PCL has an analysts' consensus of -- which suggests that it could fall by --. Given that Bangkok Dusit Medical Services PCL has higher upside potential than Bumrungrad Hospital PCL, analysts believe Bangkok Dusit Medical Services PCL is more attractive than Bumrungrad Hospital PCL.
Company Buy Ratings Hold Ratings Sell Ratings BDULFBangkok Dusit Medical Services PCL0 0 0 BUGDFBumrungrad Hospital PCL0 0 0 -
Is BDULF or BUGDF More Risky?
Bangkok Dusit Medical Services PCL has a beta of -0.028, which suggesting that the stock is 102.783% less volatile than S&P 500. In comparison Bumrungrad Hospital PCL has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BDULF or BUGDF?
Bangkok Dusit Medical Services PCL has a quarterly dividend of $0.01 per share corresponding to a yield of 3.17%. Bumrungrad Hospital PCL offers a yield of 1.86% to investors and pays a quarterly dividend of $0.09 per share. Bangkok Dusit Medical Services PCL pays 69.55% of its earnings as a dividend. Bumrungrad Hospital PCL pays out 52.75% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDULF or BUGDF?
Bangkok Dusit Medical Services PCL quarterly revenues are $805.5M, which are larger than Bumrungrad Hospital PCL quarterly revenues of $190.3M. Bangkok Dusit Medical Services PCL's net income of $127.4M is higher than Bumrungrad Hospital PCL's net income of $55.9M. Notably, Bangkok Dusit Medical Services PCL's price-to-earnings ratio is 24.31x while Bumrungrad Hospital PCL's PE ratio is 31.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services PCL is 3.63x versus 9.41x for Bumrungrad Hospital PCL. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDULFBangkok Dusit Medical Services PCL3.63x 24.31x $805.5M $127.4M BUGDFBumrungrad Hospital PCL9.41x 31.15x $190.3M $55.9M
-
Which has Higher Returns BDULF or CVM?
CEL-SCI has a net margin of 15.81% compared to Bangkok Dusit Medical Services PCL's net margin of --. Bangkok Dusit Medical Services PCL's return on equity of 15.75% beat CEL-SCI's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDULFBangkok Dusit Medical Services PCL37.83% $0.01 $3.3B CVMCEL-SCI-- -$0.11 -- -
What do Analysts Say About BDULF or CVM?
Bangkok Dusit Medical Services PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 2830.4%. Given that CEL-SCI has higher upside potential than Bangkok Dusit Medical Services PCL, analysts believe CEL-SCI is more attractive than Bangkok Dusit Medical Services PCL.
Company Buy Ratings Hold Ratings Sell Ratings BDULFBangkok Dusit Medical Services PCL0 0 0 CVMCEL-SCI1 0 0 -
Is BDULF or CVM More Risky?
Bangkok Dusit Medical Services PCL has a beta of -0.028, which suggesting that the stock is 102.783% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.939%.
-
Which is a Better Dividend Stock BDULF or CVM?
Bangkok Dusit Medical Services PCL has a quarterly dividend of $0.01 per share corresponding to a yield of 3.17%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services PCL pays 69.55% of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDULF or CVM?
Bangkok Dusit Medical Services PCL quarterly revenues are $805.5M, which are larger than CEL-SCI quarterly revenues of --. Bangkok Dusit Medical Services PCL's net income of $127.4M is higher than CEL-SCI's net income of -$7.1M. Notably, Bangkok Dusit Medical Services PCL's price-to-earnings ratio is 24.31x while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services PCL is 3.63x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDULFBangkok Dusit Medical Services PCL3.63x 24.31x $805.5M $127.4M CVMCEL-SCI-- -- -- -$7.1M
-
Which has Higher Returns BDULF or IGC?
IGC Pharma has a net margin of 15.81% compared to Bangkok Dusit Medical Services PCL's net margin of -711.67%. Bangkok Dusit Medical Services PCL's return on equity of 15.75% beat IGC Pharma's return on equity of -116.24%.
Company Gross Margin Earnings Per Share Invested Capital BDULFBangkok Dusit Medical Services PCL37.83% $0.01 $3.3B IGCIGC Pharma40.47% -$0.02 $6.4M -
What do Analysts Say About BDULF or IGC?
Bangkok Dusit Medical Services PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1254.9%. Given that IGC Pharma has higher upside potential than Bangkok Dusit Medical Services PCL, analysts believe IGC Pharma is more attractive than Bangkok Dusit Medical Services PCL.
Company Buy Ratings Hold Ratings Sell Ratings BDULFBangkok Dusit Medical Services PCL0 0 0 IGCIGC Pharma2 0 0 -
Is BDULF or IGC More Risky?
Bangkok Dusit Medical Services PCL has a beta of -0.028, which suggesting that the stock is 102.783% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.449, suggesting its more volatile than the S&P 500 by 44.948%.
-
Which is a Better Dividend Stock BDULF or IGC?
Bangkok Dusit Medical Services PCL has a quarterly dividend of $0.01 per share corresponding to a yield of 3.17%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services PCL pays 69.55% of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDULF or IGC?
Bangkok Dusit Medical Services PCL quarterly revenues are $805.5M, which are larger than IGC Pharma quarterly revenues of $257K. Bangkok Dusit Medical Services PCL's net income of $127.4M is higher than IGC Pharma's net income of -$1.8M. Notably, Bangkok Dusit Medical Services PCL's price-to-earnings ratio is 24.31x while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services PCL is 3.63x versus 16.82x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDULFBangkok Dusit Medical Services PCL3.63x 24.31x $805.5M $127.4M IGCIGC Pharma16.82x -- $257K -$1.8M
-
Which has Higher Returns BDULF or NIVF?
NewGenIvf Group has a net margin of 15.81% compared to Bangkok Dusit Medical Services PCL's net margin of --. Bangkok Dusit Medical Services PCL's return on equity of 15.75% beat NewGenIvf Group's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDULFBangkok Dusit Medical Services PCL37.83% $0.01 $3.3B NIVFNewGenIvf Group-- -- -- -
What do Analysts Say About BDULF or NIVF?
Bangkok Dusit Medical Services PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand NewGenIvf Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Bangkok Dusit Medical Services PCL has higher upside potential than NewGenIvf Group, analysts believe Bangkok Dusit Medical Services PCL is more attractive than NewGenIvf Group.
Company Buy Ratings Hold Ratings Sell Ratings BDULFBangkok Dusit Medical Services PCL0 0 0 NIVFNewGenIvf Group0 0 0 -
Is BDULF or NIVF More Risky?
Bangkok Dusit Medical Services PCL has a beta of -0.028, which suggesting that the stock is 102.783% less volatile than S&P 500. In comparison NewGenIvf Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BDULF or NIVF?
Bangkok Dusit Medical Services PCL has a quarterly dividend of $0.01 per share corresponding to a yield of 3.17%. NewGenIvf Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services PCL pays 69.55% of its earnings as a dividend. NewGenIvf Group pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BDULF or NIVF?
Bangkok Dusit Medical Services PCL quarterly revenues are $805.5M, which are larger than NewGenIvf Group quarterly revenues of --. Bangkok Dusit Medical Services PCL's net income of $127.4M is higher than NewGenIvf Group's net income of --. Notably, Bangkok Dusit Medical Services PCL's price-to-earnings ratio is 24.31x while NewGenIvf Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services PCL is 3.63x versus -- for NewGenIvf Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDULFBangkok Dusit Medical Services PCL3.63x 24.31x $805.5M $127.4M NIVFNewGenIvf Group-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will PayPal Stock Recover or Keep Sliding?
Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…
How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 34x
Alerts
Buy
56
ROOT alert for Apr 23
Root [ROOT] is up 9.37% over the past day.
Buy
72
EFX alert for Apr 23
Equifax [EFX] is up 1.69% over the past day.
Buy
51
CALX alert for Apr 23
Calix [CALX] is down 1.81% over the past day.
